Acquisition of UF Faculty Startup AbFero Provides Iron Chelators for Numerous Diseases
Late last week, Danish biotech Pharmacosmos announced it had acquired AbFero Pharmaceuticals, a University of Florida startup, for $225 million. AbFero is developing compounds called iron chelators created in Dr. Raymond Bergeron’s lab at UF. Chelators remove extra iron from the body.
Too Much Iron? Pharmacosmos Is Betting $225M on a New Potential Solution for That
Pharmacosmos is putting down $225 million to purchase AbFero, a spinout from Raymond Bergeron’s lab at the University of Florida. Its lead candidate, SP-420, recently completed Phase I safety studies as a treatment for transfusional iron overload.
Pharmacosmos Group Acquires AbFero Pharmaceuticals, Inc.
Pharmacosmos Group, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, today announced the acquisition of UF startup AbFero Pharmaceuticals, Inc., a Boston-based, privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload.
Abfero Pharmaceuticals Announces Initiation of Phase 1 Study for Lead Iron Chelator
UF startup AbFero Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO).
AbFero Pharmaceuticals Announces Funding From Cure Parkinson’s for Lead Compound SP-420
AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD).
